E-DRUG: Counterfeit medicines: the silent epidemic (2)
------------------------------------------------------
Dear friends,
I have heard nothing about the outcome of this WHO /IFPMA/ Italian
Government meeting and have my doubts about the composition of the audience
and the prominent role of IFPMA as organizer. No word about price as a
driving force for counterfeits. And too much technological solutions. RFID
labels are not for free and the equipement to make use of them is relatively
expensive. And by the way: handheld-machines to read the labels and to
re-write them are already available to everybody.
Citing " Centre for Medicines in the Public Interest" by WHO in the press is
poor science. This is a neo-liberal right wing think tank. The figure is
based on poor evidence if any at all - at least I find only a three pager
with the figure (quoted by WHO) on their homepage which mixes counterfeits
up with parallel imports in the EU and gives no references.
Patients represented by industry founded and funded IAOPO. Isn't Consumers
International the only fig leaf?
Can anyone supply more information on the outcomes of this meeting?
Jörg Schaaber MPH
BUKO Pharma-Kampagne
August-Bebel-Str. 62
33602 Bielefeld
Germany
Tel +49-(0)521-60550
Fax +49-(0)521-63789
jschaaber@bukopharma.de
www.bukopharma.de/english/